TY - JOUR
T1 - CRITICAL OBSERVATIONS ON NEUROBLASTOMA TREATMENT WITH 131-I-METAIODOBENZYLGUANIDINE AT DIAGNOSIS
AU - Mastrangelo, Renato
AU - Lasorella, Anna
AU - Iavarone, Antonio
AU - Rufini, Vittoria
AU - Troncone, Luigi
AU - Danza, Francesco
AU - Riccardi, Riccardo
PY - 1993
Y1 - 1993
N2 - Results of treatment with 131-1-Metaiodobenzylguanidine (131-I-MIBG) in
patients with resistant neuroblastoma appear encouraging if one
considers that most of the patients had far advanced, intensively
pre-treated disease. To further explore the potential role of this new
drug in untreated patients, we treated 3 children with stage III
neuroblastoma. All three of our cases received 131-I-MIBG at relatively
low dose with the complete disappearance of the tumor mass in case 1,
whereas in cases 2 and 3 CT scan showed a significant reduction of the
tumor mass and, interestingly enough, no evidence of 131-I-MIBG uptake
of a tracer dose in the remaining tumor. Particularly, in case 2, the
persistence and subsequent progression of part of the tumor mass without
131-I-MIBG uptake after a therapeutic dose of 131-I-MIBG, which
apparently destroyed the 131-I-MIBG-positive cell population, clearly
suggest heterogeneity at diagnosis, with a dual neuroblastoma cell
population, one with 131-I-MIBG uptake and the other without. Besides
the biological implications of the 131-I-MIBG uptake heterogeneity in
neuroblastoma at diagnosis, our findings suggest that in stage III
neuroblastoma patients even a relatively small dose of 131-I-MIBG
administered at diagnosis is sufficient to destroy either the primary
tumor completely (case 1) or the part of the tumor (case 2 and 3) which
shows 131-I-MIBG uptake, without any significant hematologic toxicity.
Furthermore, a single course of 131-I-MIBG at the dosage employed does
not appear to jeopardize the subsequent use of chemotherapy. In
conclusion, if our data are confirmed by further investigation,
131-I-MIBG may be included as a front line drug shortly followed by
chemotherapy in future treatment strategies of advanced neuroblastoma
without or with minimal bone marrow filtration. (C) 1993 Wiley-Liss,
Inc.
AB - Results of treatment with 131-1-Metaiodobenzylguanidine (131-I-MIBG) in
patients with resistant neuroblastoma appear encouraging if one
considers that most of the patients had far advanced, intensively
pre-treated disease. To further explore the potential role of this new
drug in untreated patients, we treated 3 children with stage III
neuroblastoma. All three of our cases received 131-I-MIBG at relatively
low dose with the complete disappearance of the tumor mass in case 1,
whereas in cases 2 and 3 CT scan showed a significant reduction of the
tumor mass and, interestingly enough, no evidence of 131-I-MIBG uptake
of a tracer dose in the remaining tumor. Particularly, in case 2, the
persistence and subsequent progression of part of the tumor mass without
131-I-MIBG uptake after a therapeutic dose of 131-I-MIBG, which
apparently destroyed the 131-I-MIBG-positive cell population, clearly
suggest heterogeneity at diagnosis, with a dual neuroblastoma cell
population, one with 131-I-MIBG uptake and the other without. Besides
the biological implications of the 131-I-MIBG uptake heterogeneity in
neuroblastoma at diagnosis, our findings suggest that in stage III
neuroblastoma patients even a relatively small dose of 131-I-MIBG
administered at diagnosis is sufficient to destroy either the primary
tumor completely (case 1) or the part of the tumor (case 2 and 3) which
shows 131-I-MIBG uptake, without any significant hematologic toxicity.
Furthermore, a single course of 131-I-MIBG at the dosage employed does
not appear to jeopardize the subsequent use of chemotherapy. In
conclusion, if our data are confirmed by further investigation,
131-I-MIBG may be included as a front line drug shortly followed by
chemotherapy in future treatment strategies of advanced neuroblastoma
without or with minimal bone marrow filtration. (C) 1993 Wiley-Liss,
Inc.
KW - I-131-METAIODOBENZYLGUANIDINE
KW - NEUROBLASTOMA
KW - RADIOPHARMACEUTICAL TREATMENT
KW - I-131-METAIODOBENZYLGUANIDINE
KW - NEUROBLASTOMA
KW - RADIOPHARMACEUTICAL TREATMENT
UR - http://hdl.handle.net/10807/16315
U2 - 10.1002/mpo.2950210604
DO - 10.1002/mpo.2950210604
M3 - Article
SN - 0098-1532
VL - 21
SP - 411
EP - 415
JO - Medical and Pediatric Oncology
JF - Medical and Pediatric Oncology
ER -